NARA Discovery
Article Details
← Back to Search Results
Journal Article

Letermovir for the compassionate therapeutic use of cytomegalovirus infection

Lorenz Schubert; Lisa Fisecker; Florian Thalhammer; Heinz Burgmann; Christoph Steininger
European Journal of Clinical Microbiology & Infectious Diseases · Vol. 40, Issue 2 · pp. 435-439 · 2021

Abstract

Purpose Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. Methods Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. Results Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). Conclusion Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.

Bibliographic Information

JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
PublisherSpringer
Publication Date2021-02-01
Publication Year2021
Volume40
Issue2
Pages435-439
Document TypeJournal Article
Print ISSN0934-9723
eISSN1435-4373
DOI10.1007/s10096-020-03990-w

Access Information

NARA Access Coverage1982-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10096
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.